贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌患者的有效性及安全性OA
Efficacy and Safety of Bevacizumab Combined with XELOX Chemotherapy Regimen in the Treatment of Patients with Metastatic Colorectal Cancer
目的:探讨贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌患者的有效性及安全性.方法:随机选取2020 年 6 月—2022 年 6 月淮南东方医院集团总医院收治的 60 例转移性结直肠癌患者.根据随机数表法将其分为对照组和观察组,各 30 例.对照组给予XELOX化疗方案,观察组在对照组基础上给予贝伐珠单抗注射液.比较两组临床疗效,治疗前后肿瘤标志物、免疫功能、生活质量及不良反应、生存率.结果:观察组总缓解率高于对照组,差异有统计学意义(P<0.05).治疗后,两组癌胚抗原(carcinoembryonic antigen,CEA)、血清淀粉样蛋白A(serum amyloid A protein,SAA)、糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)水平均低于治疗前,观察组CEA、SAA、CA19-9 水平均低于对照组,差异有统计学意义(P<0.05).治疗后,两组CD4+、CD4+/CD8+均升高,CD8+降低,观察组CD4+、CD4+/CD8+均高于对照组,CD8+低于对照组,差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组生存率高于对照组,差异有统计学意义(P<0.05).治疗后,两组社会功能、心理功能、生理功能、躯体功能评分均高于治疗前,观察组社会功能、心理功能、生理功能、躯体功能评分均高于对照组,差异有统计学意义(P<0.05).结论:贝伐珠单抗联合XELOX化疗方案可提高临床疗效和生存率,增强免疫功能,降低肿瘤标志物水平.
Objective:To explore the efficacy and safety of Bevacizumab combined with XELOX chemotherapy regimen in the treatment of patients with metastatic colorectal cancer.Method:A total of 60 patients with metastatic colorectal cancer admitted to the General Hospital of Huainan East Hospital Group from June 2020 to June 2022 were randomly selected.They were divided into control group and observation group according to random number table method,with 30 cases in each group.The control group was given XELOX chemotherapy regimen,and the observation group was given Bevacizumab Injection based on the control group.The clinical efficacy,tumor markers,immune function,quality of life before and after treatment,adverse reactions and survival rate were compared between the two groups.Result:The total remission rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the carcinoembryonic antigen(CEA),serum amyloid A protein(SAA),carbohydrate antigen 19-9(CA19-9)levels in the two groups were lower than those before treatment,and CEA,SAA and CA19-9 levels in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,CD4+ and CD4+/CD8+ increased in both groups,while CD8+ decreased,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The survival rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).After treatment,the scores of social function,psychological function,physiological function and physical function of the two groups were higher than those before treatment,and the scores of social function,psychological function,physiological function and physical function of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusion:The combination of Bevacizumab and XELOX chemotherapy regimen can improve the clinical efficacy and survival rate,enhance immune function and reduce the level of tumor markers.
张文兵;刘洁;何文霞;陈敬;曹辉
淮南东方医院集团总医院 安徽 淮南 232000
贝伐珠单抗XELOX化疗方案转移性结直肠癌有效安全性
BevacizumabXELOX chemotherapy regimenMetastatic colorectal cancerEffectivenessSecurity
《中外医学研究》 2024 (009)
10-14 / 5
评论